Filana Therapeutics (FLNA) AI Stock Analysis

• Market Cap: $96.13M
• Dividend Yield: N/A
• Average Volume (3M): 699.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: -505.96%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 48,307,896
• 10 Day Avg. Volume: 765,845
• 30 Day Avg. Volume: 699,702
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.91
• Enterprise Value/Market Cap: 0.06
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.22
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.00 ▼(-5.66% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is primarily held back by weak financial performance (no revenue, ongoing losses and cash burn, and shrinking equity/assets), with additional pressure from bearish technicals (price below key moving averages and negative MACD). Valuation is only slightly supportive because a negative P/E reflects losses and there is no dividend yield provided.

Positive Factors

Low Financial Leverage

Near-zero debt is a durable balance-sheet strength for a clinical-stage biotech: it reduces insolvency risk, preserves flexibility to raise non-debt capital for trials, and limits interest burden so more cash can be allocated to R&D rather than financing costs.

Improving Cash Burn Trend

A marked reduction in operating cash outflows in 2025 versus 2024 signals stronger cash discipline and more efficient trial spend. This improves runway prospects and reduces near-term financing pressure if the trend is sustained through program milestones.

Active Regulatory Engagement

Management's active work to address FDA requests indicates constructive engagement on the regulatory pathway—a structural factor for clinical biotechs. Continued dialogue and responsiveness can materially increase the likelihood of advancing development and potential approvals.

Negative Factors

No Revenue and Recurring Losses

The company lacks any product revenue and reports persistent operating losses, creating a structural dependence on external financing. Without commercial cash flow, long-term viability hinges on successful clinical outcomes or partner deals, which are inherently binary and uncertain.

Eroding Equity and Asset Base

Steady declines in shareholders' equity and total assets reduce the company's financial cushion and optionality. This structural erosion increases the likelihood of future dilutive financings and leaves less buffer against trial setbacks or unexpected expenses.

Near-term Cash Needs & Litigation Contingency

A material estimated litigation payment combined with ongoing negative operating cash flow creates a durable funding stress point. This raises the probability of dilutive capital raises or constrained R&D funding absent a partner or other financing solution.

Filana Therapeutics Business Overview & Revenue Model

Company Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

How the Company Makes Money

As a clinical-stage biotechnology company, Cassava Sciences has historically not had recurring commercial revenue from product sales because it does not have an FDA-approved product marketed for sale. Its cash inflows have primarily come from financing activities (such as issuing equity and, if applicable, other capital-raising transactions) used to fund research and development and clinical trials. To the extent the company generates revenue in a given period, it would typically be from sources such as collaboration, licensing, or other arrangements; however, specific, current details of material revenue-generating partnerships or recurring operating revenue streams are null.

Filana Therapeutics Financial Statement Overview

Summary

Development-stage profile with zero revenue and recurring losses. Balance sheet leverage is very low (near-zero debt), but equity and assets have declined sharply through 2025, and cash flow remains meaningfully negative despite improved burn in 2025 versus 2024.

Income Statement

Across the annual reports (2020–2025), the company reports zero revenue, consistent with an R&D-stage biotech. Losses are persistent and volatile: net income improved materially in 2024 (-$24.3M) versus 2023 (-$97.2M), but then deteriorated again in 2025 (-$91.0M). With no revenue base and recurring operating losses, near-term profitability visibility remains weak, and results appear highly dependent on spending cadence and potential future commercialization or partnering.

Balance Sheet

Leverage is very low (total debt is near-zero across periods), which is a clear balance-sheet strength. However, equity has declined sharply from $253.9M (2021) to $74.4M (2025), reflecting sustained losses and ongoing capital consumption. Total assets also trend down (from $266.8M in 2021 to $118.4M in 2025), signaling reduced financial flexibility unless the company raises additional capital.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow remaining meaningfully below zero each year—most recently 2025 operating cash flow of -$32.3M and free cash flow of -$32.8M. Cash burn improved substantially in 2025 versus 2024 (when operating cash flow was -$116.9M), but free cash flow growth remains negative in the latest period, and ongoing funding needs are likely given the absence of revenue.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-89.42M	-68.03M	0.00
EBITDA	-95.39M	-141.15M	-104.43M	-78.72M	-32.33M
Net Income	-90.97M	-24.34M	-97.22M	-76.25M	-32.38M
Balance Sheet
Total Assets	118.36M	157.53M	151.66M	234.83M	266.78M
Cash, Cash Equivalents and Short-Term Investments	95.50M	128.57M	121.14M	201.01M	233.44M
Total Debt	0.00	0.00	0.00	139.00K	236.00K
Total Liabilities	43.95M	11.83M	14.20M	7.29M	12.87M
Stockholders Equity	74.40M	145.70M	137.47M	227.54M	253.91M
Cash Flow
Free Cash Flow	-32.83M	-117.03M	-82.44M	-80.23M	-52.41M
Operating Cash Flow	-32.25M	-116.93M	-82.03M	-77.51M	-30.20M
Investing Cash Flow	-581.00K	-103.00K	-414.00K	-2.71M	-22.21M
Financing Cash Flow	-239.00K	124.47M	2.56M	47.80M	192.34M

Filana Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLNA, the sentiment is Negative. The current price of 2.12 is below the 20-day moving average (MA) of 2.17, above the 50-day MA of 2.12, and below the 200-day MA of 2.51, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 44.13 is Neutral, neither overbought nor oversold. The STOCH value of 10.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FLNA.

Filana Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMP	52 Neutral	$280.88M	-2.32	-162.49%	―	―	5.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CDXS	50 Neutral	$146.30M	3.84	-114.26%	―	-17.87%	14.42%
ANIX	49 Neutral	$94.88M	-9.85	-66.55%	―	―	11.78%
CGTX	47 Neutral	$92.69M	-5.34	-109.73%	―	―	50.39%
FLNA	44 Neutral	$96.13M	-1.05	-97.94%	―	―	-505.96%
MCRB	43 Neutral	$82.73M	23.14	15.31%	―	448.44%	―